Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia

Ivanova, Svetlana A.; Geers, Lisanne M; Hadithy, A. F. Y. Al; Pechlivanoglou, Petros; Semke, A.; Vyalova, N.; Рудиков, Е. В.; Fedorenko, Olga Yu; Wilffert, Bob; Бохан, Н. А.; Brouwers, Jacobus; Loonen, Anton J. M.

doi:10.1016/j.pnpbp.2013.12.015

Cited by 9 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Imbalance in the functioning of the dopaminergic and glutamatergic systems is associated with the failure of protective neurosteroid and neurotrophic factors shown in schizophrenia and in the development of neuroleptic induced side effects 19 . Low concentrations of DHEAS found in patients with schizophrenia and especially during prolonged schizophrenic process, contribute to hypofunction of NMDA receptors and the development of cognitive dysfunction 20 .…”

Section: Resultsmentioning

confidence: 99%

Glutamate Concentration in the Serum of Patients with Schizophrenia

et al. 2014

View full text Add to dashboard Cite

Glutamate is the major neurotransmitter with multiple functions in the central nervous system. Glutamate-mediated excitotoxicity is involved in the pathophysiological processes in schizophrenia. The purpose of this study was to determine the concentration of glutamate in the serum of patients with paranoid schizophrenia compared with healthy individuals, and depending on the duration of the schizophrenic process and leading clinical symptoms. We investigated the level of glutamate in the serum of 158 patients with paranoid schizophrenia and 94 healthy persons. Higher concentrations of glutamate in schizophrenic patients compared with healthy persons have been found. The maximum concentrations of glutamate were detected in patients with disease duration of more than ten years. Glutamate level in the serum does not depend on the prevailing negative or positive clinical symptoms. The increased concentration of glutamate can hypothetically contribute to dopaminergic and glutamatergic imbalance, leading to the development of psychotic symptoms and cognitive dysfunction

show abstract

Section: Resultsmentioning

confidence: 99%

Glutamate Concentration in the Serum of Patients with Schizophrenia

et al. 2014

View full text Add to dashboard Cite

show abstract

“…This can be attributed to increased oxidative stress within the brain due to higher activity of this oxidative cytochrome P450 enzyme system. TD is possibly related to neurotoxicity of striatal indirect pathway medium spiny neurons (Loonen and Ivanova 2013), and factors which increase the vulnerability to metabolic stress have been found to increase the likelihood of TD (Al Hadithy et al 2010;Ivanova et al 2012aIvanova et al , 2012bIvanova et al , 2014. The variation is possibly related to a difference of enzyme inducibility of cerebral CYP1A2 and CYP2D6.…”

Section: Resultsmentioning

confidence: 99%

Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility

Ivanova

Toshchakova

Филипенко

et al. 2015

The World Journal of Biological Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

“…Установлено, что цитохром P450c17α (CYP17) CYP17A1 значительно ассоциирован с АП-индуцированной ТД на уровне генотипа. Однако после коррекции по возрасту и полу выявлено, что эта связь была незначительной [38,81].…”

Section: ферменты метаболизма антипсихотиковunclassified

“…Ген CYP1A2 S. A. Ivanova и соавт. (2015) сообщили о связи между генотипом медленного метаболизма гена CYP1A2 и АП-индуцированной ТД [38,81]. Известно, что активность белка CYP17 синтезирует дегидроэпиандростерона сульфат (DHEA), антиоксидант с нейропротекторными свойствами [44].…”

Section: ферменты метаболизма антипсихотиковunclassified

“…10 CYP17 TC или TT. Носители генотипов CYP17 TC и TT имеют значительно более низкие уровни циркулирующего DHEA по сравнению с носителями аллеля Т. После корректировки по полу и возрасту не было выявлено существенной связи между генотипом CYP17 CC, аллелем T и аллелем C и концентрацией DHEA у пациентов [81]. Ген CYP1A2 расположен на длинном плече 15-й хромосомы в области 15q24 и имеет 7 экзонов, первый из которых не кодирует.…”

Section: лекции и обзорыunclassified

See 1 more Smart Citation

Candidate genes involved in the development of antipsychotic-induced tardive dyskinesia in patients with schizophrenia

Vaiman¹,

Шнайдер²,

Neznanov³

et al. 2020

Neuromuscular Diseases

View full text Add to dashboard Cite

Introduction. Drug-induced dyskinesia is an iatrogenic undesirable side reaction from the extrapyramidal system that occurs during the administration of drugs, most often antipsychotics in patients with schizophrenia. At the end of the 20 th century, studies were conducted on the search for candidate genes and the carriage of single nucleotide variants of antipsychotics-induced tardive dyskinesia. Purpose of the study – to analyze research results reflecting candidate genes and their single nucleotide variants associated with antipsychotic-induced tardive dyskinesia. Materials and methods. We searched for full-text publications in Russian and English in the eLIBRARY, PubMed, Web of Science, Springer databases using keywords (tardive dyskinesia, drug-induced tardive dyskinesia, antipsychotics, antipsychotics, typical antipsychotics, atypical antipsychotics, genes, polymorphisms) and combined searches for words over the past decade. Results. The lecture discusses candidate genes encoding proteins/enzymes involved in the pharmacodynamics and pharmacokinetics of antipsychotics Conclusion. Timely identification of individual genetic characteristics of the patient can contribute to the development of diagnostic test systems and in the future selection of the safest and most effective antipsychotic therapy.

show abstract

Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia

Cited by 9 publications

References 24 publications

Glutamate Concentration in the Serum of Patients with Schizophrenia

Glutamate Concentration in the Serum of Patients with Schizophrenia

Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility

Candidate genes involved in the development of antipsychotic-induced tardive dyskinesia in patients with schizophrenia

Contact Info

Product

Resources

About